These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38687065)

  • 21. Effects of Tocilizumab in COVID-19 patients: a cohort study.
    Vu CA; DeRonde KJ; Vega AD; Maxam M; Holt G; Natori Y; Zamora JG; Salazar V; Boatwright R; Morris SR; de Lima Corvino D; Betances AF; Colucci L; Keegan J; Lopez A; Rezk AH; Rodriguez Y; Moraru GM; Doblecki S; De La Zerda DJ; Abbo LM
    BMC Infect Dis; 2020 Dec; 20(1):964. PubMed ID: 33353546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
    Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
    BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
    Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
    J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appropriate use of tocilizumab in COVID-19 infection.
    Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
    Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol AK; Weiss A; Danahey K; Karrison TG; Edens CC; Bauer Ventura I; Pettit NN; Patel BK; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    Clin Pharmacol Ther; 2021 Mar; 109(3):688-696. PubMed ID: 33210302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.
    Jensen TO; Murray TA; Grandits GA; Jain MK; Grund B; Shaw-Saliba K; Matthay MA; Abassi M; Ardelt M; Baker JV; Chen P; Dewar RL; Goodman AL; Hatlen TJ; Highbarger HC; Holodniy M; Lallemand P; Laverdure S; Leshnower BG; Looney D; Moschopoulos CD; Mugerwa H; Murray DD; Mylonakis E; Nagy-Agren S; Rehman MT; Rupert A; Stevens R; Turville S; Weintrob A; Wick K; Lundgren J; Ko ER;
    Lancet Microbe; 2024 Jun; 5(6):e559-e569. PubMed ID: 38815595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
    Maeda T; Obata R; Rizk DO D; Kuno T
    J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
    Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
    Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.
    Jordan SC; Zakowski P; Tran HP; Smith EA; Gaultier C; Marks G; Zabner R; Lowenstein H; Oft J; Bluen B; Le C; Shane R; Ammerman N; Vo A; Chen P; Kumar S; Toyoda M; Ge S; Huang E
    Clin Infect Dis; 2020 Dec; 71(12):3168-3173. PubMed ID: 32575124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
    Tom J; Bao M; Tsai L; Qamra A; Summers D; Carrasco-Triguero M; McBride J; Rosenberger CM; Lin CJF; Stubbings W; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Kheradmand F; Rosas IO; Cai F
    Crit Care Med; 2022 Mar; 50(3):398-409. PubMed ID: 34612846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preemptive interleukin-6 blockade in patients with COVID-19.
    Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
    Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.